Therapy | Page 156 of 190 | SpiritIndia.com

Schizophrenia :: Music therapy may ease symptoms of schizophrenia

Music therapy many help to ease the depression, anxiety and emotional withdrawal symptoms of schizophrenia, British scientists said. Music therapy may provide a means of improving mental health among people with schizophrenia, but its effects in acute psychoses have not been explored. To examine the feasibility of a randomised trial of music therapy for inpatients with schizophrenia, and explore its effects on mental health, study was conducted by Dr Mike Crawford, Department of Psychological Medicine, Claybrook Centre.

Sinusitis :: New, minimally invasive surgery to treat sinusitis

If drug therapy can’t open blocked sinuses, sufferers now have a novel option. Mayo Clinic ear, nose and throat (ENT) surgeons have taken a page from the book of cardiology in performing a new, outpatient procedure to alleviate acute or chronic symptoms of sinusitis, an inflammation of the sinus cavities usually due to an infection.

Arthritis :: Botox can treat Knee Pain

Mayo Clinic seeks adults who are age 40 or older and have knee pain that has not responded to medicines, exercise or physical therapy for a research study. The purpose of this research study is to find out what effects (good and bad) the botulinum toxin (Botox) has on patients with knee arthritis. Eligible participants will have been diagnosed with knee arthritis that can be confirmed by x-ray.

Cancer :: Harnessing the Measles Virus to Attack Cancer

Mayo Clinic Cancer Center has opened a new clinical study using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme, a largely untreatable brain tumor. This is the second of several pending molecular medicine studies in patients using measles to kill cancer.

Parkinson’s Disease :: Boehringer Ingelheim’s pramipexole, mirapexin/sifrol to improve depressive and motivational symptoms

New data presented today from a meta-analysis* of nearly 1,300 Parkinson?s disease (PD) patients, indicate that pramipexole (Mirapexin?/Sifrol?) has a beneficial effect on depressive and motivational symptoms in PD.1 This confirms findings from previously published clinical trials,2,3,4 and is in addition to its established efficacy in controlling motor symptoms. These findings are of particular interest as mood symptoms in PD can affect up to 50 percent of the patient population.1,5 The data were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.

Multiple Sclerosis :: Increased sale of Copaxone drug for multiple sclerosis – Teva

COPAXONE? is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone? in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million.

Macular Degeneration :: Photoswitches could restore sight to blind retinas

A research center newly created by the University of California, Berkeley, and Lawrence Berkeley National Laboratory (LBNL) aims to put light-sensitive switches in the body’s cells that can be flipped on and off as easily as a remote control operates a TV. Optical switches like these could trigger a chemical reaction, initiate a muscle contraction, activate a drug or stimulate a nerve cell – all at the flash of a light.

Lymphoma :: Berlex Oncology Evaluating Combination Therapy for Non-Hodgkin’s Lymphoma

Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub-type of non-Hodgkin?s lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. Follicular B-cell lymphoma is an indolent, or slow-growing, type of NHL that comprises approximately 30% of all diagnosed cases.

Hepatitis :: Glaxo eltrombopag improved platelet count in hepatitis C patients with thrombocytopenia

GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. In addition, 71% - 91% of patients in all treatment groups were able to initiate antiviral therapy with pegylated interferon-α (IFN) and ribavirin, and 65% were able to be maintained on therapy.1 Full results from this Phase II study are being presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts.

Back Pain :: Physical Therapy for the Lower Back – How to Prevent and Treat Lower Back Pain

Lower back pain is one of the most common causes of job-related disability and why some people miss work. It is also the second most common neurological ailment in the United States, second only to headache. In fact, approximately 80% of adults in Western countries have, at some point, experienced lower back pain.